KeyBank National Association’s Arcutis Biotherapeutics ARQT Stock Holding History

KeyBank National Association’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$420K	Sell	16,002 -6,950	-30%	-$162K	﹤0.01%	1002
2026 Q1	$541K	Sell	22,952 -7,931	-26%	-$202K	﹤0.01%	797
2025 Q4	$897K	Sell	30,883 -14,132	-31%	-$362K	﹤0.01%	608
2025 Q3	$849K	Sell	45,015 -1,500	-3%	-$23.7K	﹤0.01%	617
2025 Q2	$652K	Hold	46,515	–	–	﹤0.01%	687
2025 Q1	$727K	Sell	46,515 -5,689	-11%	-$80.1K	﹤0.01%	627
2024 Q4	$727K	Buy	52,204 +9,680	+23%	+$106K	﹤0.01%	649
2024 Q3	$395K	Hold	42,524	–	–	﹤0.01%	879
2024 Q2	$395K	Hold	42,524	–	–	﹤0.01%	831
2024 Q1	$421K	Buy	42,524 +7,300	+21%	+$54.5K	﹤0.01%	817
2023 Q4	$114K	Buy	35,224 +22,195	+170%	+$60.3K	﹤0.01%	1058
2023 Q3	$69.2K	Hold	13,029	–	–	﹤0.01%	1016
2023 Q2	$124K	Buy	+13,029	New	+$145K	﹤0.01%	1033

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KeyBank National Association's ARQT Position: Q2 2026 in Review

KeyBank National Association reduced its Arcutis Biotherapeutics (ARQT) stake by 30% in Q2 2026, selling an estimated $162K and leaving 16,002 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

KeyBank National Association first reported a position in ARQT in Q2 2023 and has held it in 13 quarters since. The position peaked at $897K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

KeyBank National Association held 16,002 shares of Arcutis Biotherapeutics worth $420K as of Q2 2026.
KeyBank National Association sold 6,950 Arcutis Biotherapeutics shares in Q2 2026, an estimated $162K.
Arcutis Biotherapeutics made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #1002 holding.
KeyBank National Association first reported a position in Arcutis Biotherapeutics in Q2 2023 and has held it in 13 quarters since.
KeyBank National Association's Arcutis Biotherapeutics position peaked at $897K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.